High Dose Melphalan for Relapsed Myeloma
Author Information
Author(s): J.L. Mansil, D. Cunningham, C. Viner, E. Ellis, M. Meldrum, S. Milan, M. Gore
Primary Institution: Institute of Cancer Research and Royal Marsden Hospital
Hypothesis
Can repeated administration of high dose melphalan improve outcomes in patients with relapsed myeloma?
Conclusion
Repeated administration of high dose melphalan is a feasible approach for patients with relapsed myeloma, leading to significant remission rates.
Supporting Evidence
- 90% of patients received 200 mg/m2 of melphalan with an autologous bone marrow transplant.
- 55% of patients achieved complete remission and 38% achieved a partial response.
- The median duration of remission was 17 months.
- 50% of patients were alive at 58+ months after presentation.
Takeaway
This study shows that giving a strong medicine called melphalan twice can help people with a type of blood cancer called myeloma feel better.
Methodology
Patients received induction chemotherapy followed by a second course of high dose melphalan and were monitored for response and toxicity.
Potential Biases
Selection bias may exist as patients were chosen based on previous responses to treatment.
Limitations
The study does not include a randomized control group for comparison.
Participant Demographics
Median age was 43 years, with 7 females and 22 males.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website